Eurofins Scientific SE
Luxembourg · FR0014000MR3 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2024. Each line says what it is based on.
- Is it growing?Fair
- Revenue +6.7% in the year to Dec 31, 2024, on the year before.
- Is it a good business?Fair
- It earned 7.6% on its shareholders' equity in the year to Dec 31, 2024.
- Is it safe?Fair
- Equity is 49% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2024, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Revenue | €6.7B | €6.7B | €6.5B | €7.0B |
| Operating profit | €1.3B | €916M | €530M | €681M |
| Earnings per share | €4.09 | €3.17 | €1.61 | €2.13 |
| Dividend per share | €0.68 | €1.00 | n/a | €1.00 |
| Cash from operations | €1.5B | €1.1B | €1.0B | €1.3B |
| Capital spending | €444M | €576M | €478M | €454M |
| Cash | €515M | €487M | €1.2B | €614M |
| Total assets | €9.3B | €10.1B | €10.9B | €10.9B |
| Equity | €4.7B | €4.9B | €5.1B | €5.4B |
What they do
In the company's own words, from the annual report.
Eurofins Scientific, through its subsidiaries (hereafter referred to as “Eurofins” or “the Group”) is Testing for Life. Eurofins is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. It is also one of the market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing Organisations. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic (IVD) products.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.